Videos

Patient Profile: A 73-Year-Old Woman with Post-Cystectomy mUC

Gennady Bratslavsky, MD, spoke about the role of adjuvant therapy in renal cell carcinoma at the 15th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies.

Petros Grivas, MD, PhD;Shilpa Gupta, MD;Peter H. O’Donnell, MD, PhD;Thomas Powles, MBBS, MD, MRCP;Guru Sonpavde, MD

Ira Winer, MD, PhD, on Surprising Findings From ARTISTRY-1 in Ovarian Cancer

Petros Grivas, MD, PhD, introduces a patient profile of a woman with metastatic UC and invites panel members to comment on how they might approach initial treatment and management of the patient.

Ira Winer, MD, PhD, FACOG

Recent Treatment Advances in Urothelial Cancer

Ira Winer, MD, PhD, FACOG, spoke about high response rates observed in patients with pretreated platinum-resistant ovarian cancer from the phase 1/2 ARTISTRY-1 trial.

Petros Grivas, MD, PhD;Shilpa Gupta, MD;Peter H. O’Donnell, MD, PhD;Thomas Powles, MBBS, MD, MRCP;Guru Sonpavde, MD

Phillip S. Low, PhD, Discusses Next Steps in Research of 177Lu-PSMA-617 for mCRPC and Other Cancers

Petros Grivas, MD, PhD, Shilpa Gupta, MD, Peter H. O’Donnell, MD, Thomas Powles, MBBS, MRCP, MD, and Guru Sonpavde, MD, summarize recent treatment advances for patients with urothelial cancer (UC).

Phillip Low, PhD

Chronic GVHD Risk Factors and Prevention

Phillip S. Low, PhD, spoke about what the future holds for treatments like 177Lu-PSMA-617 being developed for patients with prostate cancer.

John F. D. Dipersio, MD, PhD;Yi-Bin Chen, MD;Hannah Choe, MD;Pashna N. Munshi, MD

Differences in Pathology of Acute and Chronic GVHD

Panelists consider key risk factors for chronic GVHD, including the degree of donor transplant matching, patient age, intensity of conditioning, use of ablative doses of total-body radiation, and presence of acute GVHD.

John F. D. Dipersio, MD, PhD;Yi-Bin Chen, MD;Hannah Choe, MD;Pashna N. Munshi, MD

Ursula A. Matulonis, MD, on Key Findings With Mirvetuximab Soravtansine in FRα-High Ovarian Cancer

Pashna N. Munshi, MD, and Yi-Bin Chen, MD, examine key differences in the pathologic features of acute and chronic GVHD.

Ursula A. Matulonis, MD

Matthew Krebs, MB, PhD, Talks Rationale for the PALOMA Trial of Subcutaneous Amivantamab in Solid Tumors

Ursula A. Matulonis, MD, discusses key data with mirvetuximab soravtansine for patients with folate receptor α–high platinum-resistant ovarian cancer that read out of the phase 3 SORAYA trial.

Matthew Krebs, MB, PhD

AR Inhibitor Selection in Nonmetastatic Castration-Resistant Prostate Cancer

Matthew Krebs, MB, PhD spoke about the reasoning for the phase 1 PALOMA trial in patients with solid tumors who received a subcutaneous formulation of amivantamab.

Robert Dreicer, MD, MS, FACP;Saby George, MD;Mark Scholz, MD

Patient Scenario 1: nmCRPC Identification and Work-up

Shared insight on the selection of specific androgen receptor inhibitors for patients with nonmetastatic castration-resistant prostate cancer.

Robert Dreicer, MD, MS, FACP;Saby George, MD;Mark Scholz, MD

Stéphane Champiat, MD, PhD, Reviews Results With IL-2/IL15 Superagonist SOT101 From AURELIO-03 Trial

Centering the discussion around a patient with nonmetastatic castration-resistant prostate cancer, experts share insight on optimal work-up and testing.

Stéphane Champiat, MD, PhD

Discontinuing IO/IO Therapy in Intermediate-Risk Renal Cell Carcinoma

Stéphane Champiat, MD, PhD, spoke about the results of the AURELIO-03 trial with SOT101 and pembrolizumab for patients with advanced solid tumors.

Robert J. Motzer, MD;David Aggen, MD, PhD;Robert S. Alter, MD;Mehmet Asim Bilen, MD;Brian I. Rini, MD

RRMM: Ixazomib Plus Pomalidomide and Dexamethasone

Shared insight on the adverse event profile of immunotherapy combination regimens in renal cell carcinoma, including advice on when it is appropriate to discontinue therapy.

Paul G. Richardson, MD;Cristina Gasparetto, MD

Patient Profile 2: Intermediate-Risk RCC Treated With Ipilimumab + Nivolumab

Expert perspectives on the triplet combination of ixazomib, pomalidomide, and dexamethasone in multiple myeloma presented at the 2021 ASH [American Society of Hematology] Annual Meeting.

Robert J. Motzer, MD;David Aggen, MD, PhD;Robert S. Alter, MD;Mehmet Asim Bilen, MD;Brian I. Rini, MD

Importance of MRD in Treating Patients With Multiple Myeloma

Expert perspectives on the clinical scenario of a patient with intermediate-risk renal cell carcinoma, who is managed with the immunotherapy combination of ipilimumab and nivolumab.

Paul G. Richardson, MD;Cristina Gasparetto, MD

Frederick Locke, MD, Discusses Recent Approval of Axi-Cel in Relapsed/Refractory LBCL

Continuing their discussion on the management of multiple myeloma, experts Paul Richardson, MD, and Cristina Gasparetto, MD, consider the value of minimal residual disease as a marker.

$Frederick Locke, MD, Discusses Recent Approval of Axi-Cel in Relapsed/Refractory LBCL$

Frederick Locke, MD

Evolving Treatment Landscape in Metastatic Prostate Cancer

Frederick Lock, MD, spoke about the approval of axicabtagene ciloleucel and how it’s beneficial for patients with large B-cell lymphoma who were treated with frontline chemoimmunotherapy.

Bobby Liaw, MD

Recent Updates in Prostate Cancer Care

A prostate cancer expert discusses promising and emerging treatments for prostate cancer.

Atish Choudhury, MD, PhD

Frontline Treatment Options for RAI-refractory DTC

Dr Choudhury shares recent updates from 2021 meetings including ASCO GU, AUA, and ESMO.

$Frontline Treatment Options for RAI-refractory DTC$

Lori Wirth, MD

Impact of GVHD on Leukemic Relapse and Patient Outcomes

Lori Wirth, MD, defines radioiodine-refractory differentiated thyroid cancer and discusses frontline treatment options for patients with the disease.

John F. D. Dipersio, MD, PhD;Yi-Bin Chen, MD;Hannah Choe, MD;Pashna N. Munshi, MD

April 7th 2022

Hannah Choe, MD, guides the panel in a conversation on the protective effects of acute and chronic GVHD including the potential impact on leukemic relapse.

Defining Acute and Chronic GVHD: Signs and Symptoms

John F. D. Dipersio, MD, PhD;Yi-Bin Chen, MD;Hannah Choe, MD;Pashna N. Munshi, MD

April 7th 2022

A panel of key opinion leaders in stem cell transplant and cellular immunotherapy reviews the hallmark signs and symptoms of acute GVHD.

Peter Humphrey, MD, PhD, Talks Multidisciplinary Aspects of Oncology Research

Peter Humphrey MD, PhD

April 7th 2022

At the 15th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies, Peter Humphrey, MD, PhD, spoke about how the conference catered to the multidisciplinary audience, and what he learned from that.

Anjali Y. Hari, MD, speaks to the rationale for examining hyperthermic intraperitoneal chemotherapy in a population of frail and non-frail patients with ovarian cancer.

Anjali Hari, MD, Highlights the Rationale for Assessing HIPEC in Frail and Non-Frail Ovarian Cancer

Anjali Hari, MD

ADT Therapy in Prostate Cancer: Agonists vs Antagonists

Anjali Y. Hari, MD, speaks to the rationale for examining hyperthermic intraperitoneal chemotherapy in a population of frail and non-frail patients with ovarian cancer.

Robert Dreicer, MD, MS, FACP;Saby George, MD;Mark Scholz, MD

Overview on Androgen Deprivation Therapy in Prostate Cancer

Expert perspectives on the use of LHRH agonists versus antagonists in the management of prostate cancer.

Robert Dreicer, MD, MS, FACP;Saby George, MD;Mark Scholz, MD

Ursula A. Matulonis, MD, Highlights the Potential of Mirvetuximab Soravtansine in FRα-High Ovarian Cancer

A comprehensive overview on androgen-deprivation therapy in prostate cancer and the various therapeutic agents it consists of.

Ursula A. Matulonis, MD